K&F’s first post-pandemic jury trial resulted in a $10.6 million verdict for the widow of a mesothelioma victim.

Food and Drug Administration recalls diabetes drug

For those in Ohio and across the country who struggle with diabetes, maintaining a healthy glucose level is essential. High glucose levels can lead to serious complications, and many with diabetes rely on medications to help them regulate those levels and remain healthy. Unfortunately, according to a drug recall recently published by the U.S. Food and Drug Administration, even those drugs may place people at risk.

A commonly used medication for lowering glucose levels in diabetic patients is now the subject of a recall. Marksans Pharma Limited, the manufacturer of metformin hydrochloride extended-release tablets, has recalled the medication because it apparently contains high levels of cancer-causing contaminants. Marksans Pharma Limited manufactures the drugs in India and distributes them in the United States and elsewhere. However, Marksans products are not the only ones that contain the contaminants.

Widespread danger

At least seven other manufacturers of metformin have recalled their tablets. The recalls state that the drugs contain higher than acceptable levels of N-nitrosodimethylamine, or NDMA, which is a human carcinogen. Earlier this year, the FDA alerted patients to a recall of Zantac prescription heartburn medication for similar NDMA contamination.

While the U.S. Food and Drug Administration continues its investigation, those in Ohio and beyond who rely on prescription medications may have concerns about the safety of those drugs. Drug manufacturers have a heavy responsibility to ensure their products are of the highest quality and levels of safety for their customers. Neglecting to reach these goals may leave patients dealing with life and death concerns.

Archives

$120 Million Settlement

To 15,000 Asbestos Victims

$20 Million Verdict

Mesothelioma

$17 Million Verdict

Mesothelioma

$8.2 Million Verdict

Mesothelioma

White Paper Read Now2
White Paper Read Now